|
1
|
Wong MCS, Lao XQ, Ho KF, Goggins WB and
Tse SLA: Incidence and mortality of lung cancer: Global trends and
association with socioeconomic status. Sci Rep. 7:143002017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer Statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Penz E, Watt KN, Hergott CA, Rahman NM and
Psallidas I: Management of malignant pleural effusion: Challenges
and solutions. Cancer Manag Res. 9:229–241. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi H: Guidelines to the diagnosis and
treatment of malignant pleural effusion. Chin J Intern Med.
53:166–167. 2014.
|
|
5
|
Zachary I: Signaling mechanisms mediating
vascular protective actions of vascular endothelial growth factor.
Am J Physiol Cell Physiol. 280:C1375–C1386. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ide AG, Baker NH and Warren SL:
Vascularization of the brown pearce rabbit epithelioma transplant
as seen in the transparent ear chamber. Am J Roentgenol.
42:891–899. 1939.
|
|
7
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Senger DR, Galli SJ, Dvorak AM, Perruzzi
CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid.
Science. 219:983–985. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferrara N and Henzel WJ: Pituitary
follicular cells secrete a novel heparin-binding growth factor
specific for vascular endothelial cells. Biochem Biophys Res
Commun. 161:851–858. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Vries C, Escobedo JA, Ueno H, Houck K,
Ferrara N and Williams LT: The fms-like tyrosine kinase, a receptor
for vascular endothelial growth factor. Science. 255:989–991. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Harmey JH and Bouchier-Hayes D: Vascular
endothelial growth factor (VEGF), a survival factor for tumor
cells: Implications for anti-angiogenic therapy. Bioessays.
24:280–283. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bradshaw M, Mansfield A and Peikert T: The
role of vascular endothelial growth factor in the pathogenesis,
diagnosis and treatment of malignant pleural effusion. Curr Oncol
Rep. 15:207–216. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zang J, Hu Y, Xu X, Ni J, Yan D, Liu S, He
J, Xue J, Wu J and Feng J: Elevated serum levels of vascular
endothelial growth factor predict a poor prognosis of
platinum-based chemotherapy in non-small cell lung cancer. Onco
Targets Ther. 10:409–415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Popper HH: Progression and metastasis of
lung cancer. Cancer Metastasis Rev. 35:75–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu CP: Interpretation of expert consensus
2014 on diagnosis and treatment of malignant pleural effusion. J
Transl Int Med. 3:1–2. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dvorak HF: Vascular permeability
factor/vascular endothelial growth factor: A critical cytokine in
tumor angiogenesis and a potential target for diagnosis and
therapy. J Clin Oncol. 20:4368–4380. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fafliora E, Hatzoglou C, Gourgoulianis KI
and Zarogiannis SG: Systematic review and meta-analysis of vascular
endothelial growth factor as a biomarker for malignant pleural
effusions. Physiol Rep. 4:e129782016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sriram KB, Relan V, Clarke BE, Duhig EE,
Yang IA, Bowman RV, Lee YC and Fong KM: Diagnostic molecular
biomarkers for malignant pleural effusions. Future Oncol.
7:737–752. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu Y, Zhang M, Li GH, Gao JZ, Guo L, Qiao
XJ, Wang LH, He L, Wang ML, Yan L and Fu XH: Diagnostic values of
vascular endothelial growth factor and epidermal growth factor
receptor for benign and malignant hydrothorax. Chin Med J (Engl).
128:305–309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou WB, Bai M and Jin Y: Diagnostic value
of vascular endothelial growth factor and endostatin in malignant
pleural effusions. Int J Tunerc Lung Dis. 13:381–386. 2009.
|
|
21
|
Nam HS: Malignant pleural effusion:
Medical approaches for diagnosis and management. Tuberc Respir Dis
(Seoul). 76:211–217. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Y, Liang B, Zhao YJ, Wang SC, Fan YB
and Wu GP: Transcription expression and clinical significance of
vascular endothelial growth factor mRNA and endostatin mRNA in
pleural effusions of patients with lung cancer. Diagn Cytopathol.
40:287–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jiang B, Wu GP, Zhao YJ and Wang SC:
Transcription expression and clinical significance of TTF-1 mRNA in
pleural effusion of patients with lung cancer. Diagn Cytopathol.
36:849–854. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Palaoro LA, Blanco AM, Gamboni M, Rocher
AE and Rotenberg RG: Usefulness of ploidy, AgNor and
immunocytochemistry for differentiating benign and malignant cells
in serous effusions. Cytopathology. 18:33–39. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Light RW: Pleural effusions. Med Clin
North Am. 95:1055–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu QF: Clinical value of VEGF combined
with CEA in the treatment of malignant pleural effusion of advanced
NSCLC. Practical Oncol J (China). 27:156–159. 2013.
|
|
27
|
Stathopoulos GT and Kalomenidis I:
Malignant pleural effusion: Tumor-host interactions unleashed. Am J
Respir Crit Care Med. 186:487–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamed EA, El-Noweihi AM, Mohamed AZ and
Mahmoud A: Vasoactive mediators (VEGF and TNF-alpha) in patients
with malignant and tuberculous pleural effusions. Respirology.
9:81–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gerber HP and Ferrara N: Pharmacology and
pharmacodynamics of bevacizumab as monotherapy or in combination
with cytotoxic therapy in preclinical studies. Cancer Res.
65:671–680. 2005.PubMed/NCBI
|
|
30
|
Numnum TM, Rocconi RP, Whitworth J and
Barnes MN: The use of bevacizumab to palliate symptomatic ascites
in patients with refractory ovarian carcinoma. Gynecol Oncol.
102:425–428. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pritchard-Jones RO, Dunn DB, Qiu Y, Varey
AH, Orlando A, Rigby H, Harper SJ and Bates DO: Expression of VEGF
(XXX)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br
J Cancer. 97:223–230. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fontanini G, Lucchi M, Vignati S, Mussi A,
Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA
and Bevilacqua G: Angiogenesis as a prognostic indicator of
survival in nonsmall-cell lung carcinoma: A prospective study. J
Natl Cancer Inst. 89:881–886. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ferrara N: Vascular endothelial growth
factor: Basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Voelkel NF, Vandivier RW and Tuder RM:
Vascular endothelial growth factor in the lung. Am J Physiol Lung
Cell Moistiol. 290:L209–L221. 2006. View Article : Google Scholar
|
|
37
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mayerhofer M, Valent P, Sperr WR, Griffin
JD and Sillaber C: BCR/ABL induces expression of vascular
endothelial growth factor and its transcriptional activator,
hypoxia induciblefactor-1alpha, through a pathway involving
phosphoinositide 3-kinase and the mammalian target of rapamycin.
Blood. 100:3767–3775. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Loeffler S, Fayard B, Weis J and
Weissenberger J: Interleukin-6 induces transcriptional activation
of vascular endothelial growth factor (VEGF) in astrocytes in vivo
and regulates VEGF promoter activity in glioblastoma cells via
direct interaction between STAT3 and Sp1. Int J Cancer.
115:202–213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cohen T, Nahari D, Cerem LW, Neufeld G and
Levi BZ: Interleukin 6 induces the expression of vascular
endothelial growth factor. J Biol Chem. 271:736–741. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wójcik E, Jakubowicz J, Skotnicki P,
Sas-Korzyńska B and Kulpa JK: IL-6 and VEGF in small cell lung
cancer patients. Anticancer Res. 30:1773–1778. 2010.PubMed/NCBI
|
|
42
|
Yan J, Jiang Y and Xu H: Endu treatment of
malignant pleural effusion. Practical J Cancer. 27:538–539.
2012.
|
|
43
|
O'Reilly MS, Boehm T, Shing Y, Fukai N,
Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hayes AJ, Li LY and Lippman ME: Science,
medicine, and the future. Antivascular therapy: A new approach to
cancer treatment. BMJ. 318:853–856. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xu X, Mao W, Chen Q, Zhuang Q, Wang L, Dai
J, Wang H and Huang Z: Endostar, a modified recombinant human
endostatin, suppresses angiogenesis through inhibition of
Wnt/β-catenin signaling pathway. PLoS One. 9:e1074632014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rong B, Yang S, Li W, Zhang W and Ming Z:
Systematic review and meta-analysis of Endostar (rh-endostatin)
combined with chemotherapy versus chemotherapy alone for treating
advanced non-small cell lung cancer. World J Surg Oncol.
10:1702012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mohajeri A, Sanaei S, Kiafar F, Fattahi A,
Khalili M and Zarghami N: The challenges of recombinant endostatin
in clinical application: Focus on the different expression systems
and molecular bioengineering. Adv Pharm Bull. 7:21–34. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shichiri M and Hirata Y: Antiangiogenesis
signals by endostatin. FASEB J. 15:1044–1053. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hajitou A, Grignet C, Devy L, Berndt S,
Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM and
Noël A: The antitumoral effect of endostatin and angiostatin is
associated with a down-regulation of vascular endothelial growth
factor expression in tumor cells. FASEB J. 16:1802–1804. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li DH, Liu QG, Wang HP, Yu M, Jiang J,
Tang CH and Ning YL: Study on recombinant human endostatin in the
treatment of malignant pleural effusion in the elderly. Shaanxi Med
J. 44:1138–1139. 2015.(In Chinese).
|
|
51
|
Murakami A, Tabata C, Tabata R, Okuwa H
and Nakano T: Clinical role of pleural effusion MMP-3 levels in
malignant pleural mesothelioma. Oncol Lett. 3:581–585. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ma X, Yao Y, Yuan D, Liu H, Wang S, Zhou C
and Song Y: Endostar suppresses angiogenesis and lymphangiogenesis
of malignant pleural effusion in mice. PLoS One. 7:e534492012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda
M, Hayashi Y, Takanashi Y and Kitamura H: Enhancement of pleural
treatment and lymph node metastasis of intrathoracic lung cancer
cells by vascular endothelial growth factors (VEGFs). Lung Cancer.
45:325–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Prager GW, Lackner EM, Krauth MT, Unseld
M, Poettler M, Laffer S, Cerny-Reiterer S, Lamm W, Kornek GV, et
al: Targeting of VEGF dependent transendothelial migration of
cancer cells by bevacizumab. Mol Oncol. 4:150–160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K,
Zhu Y, Zhou Q, Hou M, Guan Z, et al: Results of randomized,
multicenter, double-blind phase III trial of rh-endostatin (YH-16)
in treatment of advanced non-small cell lung cancer patients.
Zhongguo Fei Ai Za Zhi. 8:283–290. 2005.(In Chinese). PubMed/NCBI
|
|
56
|
Qin S, Yang L, Liang J, Cheng Y, Tan Q, Bi
J, Wang L, Hu B, Shi J, Sun G, et al: Prospective, randomized,
multicenter clinical study of endometrial and cisplatin in the
treatment of malignant pleural effusion. Chin J Clin Oncol.
22:193–202. 2017.(In Chinese).
|
|
57
|
Hu X, Shi Y, Wang H, Zhang C, Liu P, Wang
Y and Li J: A clinical study on intra-thoracic chemotherapy of
recombinant human endostatin combined with cisplatin for malignant
pleural effusion. Clin Med J. 3:23–27. 2015.
|
|
58
|
Wei H, Qin S, Yin X, Chen Y and Hua H:
Endostar inhibits ascites formation and prolonged survival in mouse
models of malignant ascites. Oncol Lett. 9:2694–2700. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Qin S, Liu X, Wang L, Chen Y, Qian J, Hui
H, Gong X, Yang L and He Z: Clinical study of recombinant human
endostatin combined with chemotherapy in the treatment of advanced
malignant tumors of lung. Clin J Onol. 34:426–428. 2012.(In
Chinese).
|
|
60
|
Kisker O, Becker CM, Prox D, Fannon M,
D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR
and Folkman J: Continuous administration of endostatin by
intraperitoneally implanted osmotic pump improves the efficacy and
potency of therapy in a mouse xenograft tumor model. Cancer Res.
61:7669–7674. 2011.
|
|
61
|
Shen H, Zhao J, Weng SS, Fang XF, Zhang YY
and Huang JJ: Continuous administration of endostar plus GP
chemotherapy in local advanced or metastatis lung squamous cell
carcinoma. Acta Medica Mediterr. 32:57–62. 2016.
|
|
62
|
Qin M: Clinical observation of cisplatin
plus endostar endovascular infusion in the treatment of advanced
non-small cell lung cancer with malignant pleural effusion. China
Pract Med. 11:228–229. 2016.
|
|
63
|
Xu J, Qi DL, Li XB and Wang RX:
Recombinant human endostatin combined with chemotherapy in the
treatment of malignant pleural effusion of non-small cell lung
cancer. Chin J Clin Oncol. 24:1573–1576. 2014.
|
|
64
|
Huang L: Clinical observation on treatment
of malignant pleural effusion of Non-small cell lung cancer with.
Jilin Med. 35:4308–4309. 2014.
|
|
65
|
Yang Y, Lin R and Cao G: Combined with
cisplatin in the treatment of malignant pleural effusion in
non-small cell lung cancer. Chin Med. 22:21–22. 2013.
|
|
66
|
Liu W, Ham M, Yin N and Li J: Clinical
study on the treatment of non-small cell lung cancer with malignant
pleural effusion by intrapleural injection with. Shandong
Pharmaceutical. 50:79–80. 2010.
|
|
67
|
Huang J: Observation on the therapeutic
effect of Endu combined with cisplatin intrapleural injection on
malignant pleural effusion. J Clin Med Practical. 13:63–64.
2010.
|
|
68
|
Li W: Observation of curative effect of
intrapleural perfusion of malignant pleural effusion. J Med Forum.
32:170–172. 2011.
|
|
69
|
Tu J: Clinical study of recombinant human
endostatin combined with intrapleural injection of cisplatin in the
treatment of malignant pleural effusion of non-small cell lung
cancer. Pract J Cancer. 12:1592–1594. 2014.(In Chinese).
|
|
70
|
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S,
Feng J, He J, Han B, Wang J, et al: BEYOND: A randomized,
double-blind, placebo-controlled, multicenter, phase III study of
first-line carboplatin/paclitaxel plus bevacizumab or placebo in
Chinese patients with advanced or recurrent nonsquamous
non-small-cell lung cancer. J Clin Oncol. 33:2197–2204. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Shibuya M: Vascular endothelial growth
factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A
crucial target for anti- and pro-angiogenic therapies. Genes
Cancer. 2:1097–1105. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wu Z, Wu Q, Sun D, Wang Z, Shi Y and Dai
G: Progress in response prediction for Bevacizumab in anti-tumor
therapy. Prog Mod Bio. 14:4570–4573. 2014.
|
|
73
|
Guan F, Li Z, Yuan S and Gao J: Current
status and clinical application of bevacizumab. Chin Sci.
12:302016.
|
|
74
|
Tamiya M, Tamiya A, Yamadori T, Nakao K,
Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, et
al: Phase 2 study of bevacizumab with carboplatin-paclitaxel for
non-small cell lung cancer with malignant pleural effusion. Med
Oncol. 30:6762013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hsu LH, Hsu PC, Liao TL, Feng AC, Chu NM
and Kao SH: Pleural fluid osteopontin, vascular endothelial growth
factor and urokinase-type plasminogen activator levels as
predictors of pleurodesis outcome and prognosticators in patients
with malignant pleural effusion: A prospective cohort study. BMC
Cancer. 16:4632016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lin FH, Su WP and Jin R: Clinical study of
bevacizumab combined with cisplatin in the treatment of malignant
pleural effusion of non-small cell lung cancer. Clin J Clin Med.
44:698–700. 2010.(In Chinese).
|
|
77
|
Chi J, Bai Y and Chen H: Clinical study of
bevacizumab combined with carboplatin in the treatment of malignant
pleural effusion of non-small cell lung cancer. Chin J Clin
Pharmacol. 13:1175–1180. 2016.(In Chinese).
|
|
78
|
Chen L and Xia SY: Effects and safety of
bevacizumab combined with cisplatin in the treatment of malignant
pleural effusion of non-small cell lung cancer. J Shanghai Jiaotong
Univ. 8:1194–1198. 2015.
|
|
79
|
Qu B, Jiang W and Zhou Z: Clinical study
of bevacizumab combined with cisplatin in the treatment of
malignant pleural effusion of non-small cell lung cancer. J Chin
Med Univ. 7:648–652. 2015.(In Chinese).
|
|
80
|
Huang B: Efficacy of bevacizumab combined
with cisplatin in the treatment of malignant pleural effusion in
non-small cell lung cancer. Intern J Resp Dis. 11:814–817.
2016.
|
|
81
|
Han N, Zhang MX, Yu SY and Cheng Y:
Clinical study of bevacizumab combined with cisplatin/pemetrexed in
the treatment of malignant pleural effusion of non-squamous cell
carcinoma of non-squamous cell carcinoma. J Huazhong Univ Sci Tech.
5:588–591. 2013.
|
|
82
|
Liu HP, Gong CP, Qu L, Li X, Hu HT and
Zhang YL: Efficacy of bevacizumab combined with
cisplatin/pemetrexed in the treatment of malignant pleural effusion
of non-small cell lung cancer. Med J Nat Defending Forces Southwest
Chin. 12:1148–1151. 2016.
|
|
83
|
Lu J, Xie Q, Chen Q, Sun WH, Zhong AH, Shi
Q, Liao SX and Zhu JX: The expression of BRMS1 in lung cancer and
its effect on invasion and metastasis of lung cancer cells. J Clin
Pulmonary Med. 9:1664–1667. 2016.
|
|
84
|
Usui K, Sugawara S, Nishitsuji M, Fujita
Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, et
al: A phase II study of bevacizumab with carboplatin-pemetrexed in
non-squamous non-small cell lung carcinoma patients with malignant
pleural effusions: North East Japan Study Group Trial NEJ013A. Lung
Cancer. 99:131–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Masago K, Fujimoto D, Fujita S, Hata A,
Kaji R, Ohtsuka K, Okuda C, Takeshita J and Katakami N: Response to
bevacizumab combination chemotherapy of malignant pleural effusions
associated with non-squamous non-small-cell lung cancer. Mol Clin
Oncol. 3:415–419. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tamiya M, Tamiya A, Yasue T, Nakao K,
Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H,
et al: Vascular endothelial growth factor in plasma and pleural
effusion is a biomarker for outcome after bevacizumab plus
carboplatin-paclitaxel treatment for non-small cell lung cancer
with malignant pleural effusion. Anticancer Res. 36:2939–2944.
2016.PubMed/NCBI
|
|
87
|
Gkiozos I, Tsagouli S, Charpidou A, Grapsa
D, Kainis E, Gratziou C and Syrigos K: Levels of vascular
endothelial growth factor in serum and pleural fluid are
independent predictors of survival in advanced non-small cell lung
cancer: Results of a prospective study. Anticancer Res.
35:1129–1137. 2015.PubMed/NCBI
|
|
88
|
Zhang Y, Yu LK, Lu GJ, Xia N, Xie HY, Hu
W, Hao KK, Xu CH and Qian Q: Prognostic values of VEGF and
Endostatin with malignant pleural effusions in patients with lung
cancer. Asian Pac J Caner Prev. 15:8435–8440. 2014. View Article : Google Scholar
|
|
89
|
Hooper CE, Elvers KT, Welsh GI, Millar AB
and Maskell NA: VEGF and sVEGFR-1 in malignant pleural effusions:
Association with survival and pleurodesis outcomes. Lung Cancer.
77:443–449. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Sandler AB, Johnson DH and Herbst RS:
Anti-vascular endothelial growth factor monoclonals in non-small
cell lung cancer. Clin Cancer Res. 10:4258–4262. 2004. View Article : Google Scholar
|
|
91
|
Kitamura K, Kubota K, Ando M, Takahashi S,
Nishijima N, Sugano T, Toyokawa M, Miwa K, Kosaihira S, Noro R, et
al: Bevacizumab plus chemotherapy for advanced non-squamous
non-small-cell lung cancer with malignant pleural effusion. Cancer
Chemother Pharmacol. 71:457–461. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Wakelee HA, Dahlberg SE, Keller SM, Tester
WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC,
Rothman JM, et al: Adjuvant chemotherapy with or without
bevacizumab in patients with resected non-small-cell lung cancer
(E1505): An open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 18:1610–1623. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Assoun S, Brosseau S, Steinmetz C, Gounant
V and Zalcman G: Bevacizumab in advanced lung cancer: State of the
art. Future Oncol. 13:2515–2535. 2017. View Article : Google Scholar : PubMed/NCBI
|
